Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Jewell, EL, Smrtka, M, Broadwater, G, Valea, F, Davis, DM, Nolte, KC, Valea, R, Myers, ER, and Havrilesky, LJ. "Preference-based utility scores for adverse events associated with the treatment of gynecologic cancers." Int J Gynecol Cancer 23, no. 6 (July 2013): 1158-1166.

Full Text

Lopez-Acevedo, M, Havrilesky, LJ, Broadwater, G, Kamal, AH, Abernethy, AP, Berchuck, A, Alvarez Secord, A, Tulsky, JA, Valea, F, and Lee, PS. "Timing of end-of-life care discussion with performance on end-of-life quality indicators in ovarian cancer." Gynecologic Oncology 130, no. 1 (July 2013): 156-161.

Full Text

Secord, AA, Barnett, JC, Ledermann, JA, Peterson, BL, Myers, ER, and Havrilesky, LJ. "Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer." Int J Gynecol Cancer 23, no. 5 (June 2013): 846-852.

Full Text

Havrilesky, LJ, Gierisch, JM, Moorman, PG, Coeytaux, RR, Urrutia, RP, Lowery, WJ, Dinan, M, McBroom, AJ, Wing, L, Musty, MD, Lallinger, KR, Hasselblad, V, Sanders, GD, and Myers, ER. "Oral contraceptive use for the primary prevention of ovarian cancer." Evidence report/technology assessment, no. 212 (June 2013): 1-514. (Review)

Scholars@Duke

Stine, JE, Pierce, S, Gehrig, PA, Nakayama, J, Havrilesky, LJ, Secord, AA, Chiu, WK, Moore, DT, and Kim, KH. "Recurrence rates in patients with uterine papillary serous cancer with and without breast cancer." May 20, 2013.

Scholars@Duke

Ko, EM, Walter, P, Clark, LH, Jackson, AL, Franasiak, J, Havrilesky, LJ, Secord, AA, Moore, DT, Gehrig, PA, and Bae-Jump, VL. "The impact of diabetes and obesity on endometrial cancer outcomes." May 20, 2013.

Scholars@Duke

Havrilesky, LJ, Kulasingam, SL, Jewell, EL, and Cohn, DE. "Comparative effectiveness research in gynecologic oncology." In Principles and Practice of Gynecologic Oncology: Sixth Edition, 503-517. May 8, 2013.

Scholars@Duke

Bolac, CS, Wallace, AH, Broadwater, G, Havrilesky, LJ, and Habib, AS. "The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer." Anesth Analg 116, no. 5 (May 2013): 1041-1047.

Full Text

Hanna, RK, Poniewierski, MS, Laskey, RA, Lopez, MA, Shafer, A, Van Le, L, Crawford, J, Dale, DC, Gehrig, PA, Secord, AA, Havrilesky, LJ, and Lyman, GH. "Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer." Gynecol Oncol 129, no. 1 (April 2013): 74-80.

Full Text

Kulasingam, SL, Havrilesky, LJ, Ghebre, R, and Myers, ER. "Screening for cervical cancer: a modeling study for the US Preventive Services Task Force." Journal of Lower Genital Tract Disease 17, no. 2 (April 2013): 193-202.

Full Text

Pages